Clinical Trial Update: A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy [Phase 3]

View source ↗

Summary

A long-term extension study evaluating a one-month degarelix dosing regimen for prostate cancer requiring androgen ablation therapy (Phase 3) has completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Firmagon (Degarelix)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2013-03-21